Cross-Sector entity
The 50-day window averages about 0.6 stories each week. The busiest single day carried 2. Of the tracked stories, 1 of 4 also mention AstraZeneca Plc, the most common co-covered peer. The clearest coverage concentration is markets: 2 of 4 stories, with the rest divided among 2 other categories.
4 verified stories tracked
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
The 50-day window averages about 0.6 stories each week. The busiest single day carried 2. Of the tracked stories, 1 of 4 also mention AstraZeneca Plc, the most common co-covered peer. The clearest coverage concentration is markets: 2 of 4 stories, with the rest divided among 2 other categories. The tracked stories average 2 original sources each. This profile follows 4 Cross-Sector stories mentioning Bank of America Corp DE across the period from June 28, 2026 to August 16, 2026.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bank of America Corp DE. Shared-story counts are live from our verified record — not editorial picks.
13F activity reported by financial media
HoldingsChannel and Bbns publish details on Oppenheimer's new position and other institutional moves in Chubb.
Insider sale by EVP Joseph F. Wayland
Wayland sells 8,502 shares at an average price of $364.54, totaling $3,099,319.08 and reducing direct ownership by 20.12% to 33,749 shares.
Q2 2026 13F reporting period ends
Oppenheimer Asset Management builds a new 118,585-share Chubb position during the quarter, valued at approximately $40,407,000.
Oppenheimer Asset Management initiated a $40.4M position in Chubb during Q2 2026, joining late-stage buying from Berkshire, State Street, T. Rowe, GQG, and BofA. Institutional ownership now stands at 83.81%, but a $3.1M insider sale by EVP Joseph Wayland adds nuance.
Source: The Lincolnian Online · Bbns
Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Source: tickerreport.com · dailypolitical.com
Six major institutional investors have collectively added over 3.8 million AstraZeneca shares across recent quarters, signaling strong professional confidence in the company's diversified healthcare portfolio spanning oncology, cardiovascular, respiratory, and rare disease treatments. The sustained buying pattern highlights institutional conviction in AstraZeneca's ability to deliver innovative therapies that address critical unmet medical needs.
Source: Ticker Report · Watch List News
A wave of institutional buying in NVIDIA highlights the stock’s allure, with Paragon Capital’s Q1 2026 filing revealing a 288.8% stake increase. The move underscores how deep the conviction runs among hedge funds and sovereign wealth funds.
Source: Zolmax · Markets Daily
